{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T17:00:56Z","timestamp":1780246856173,"version":"3.54.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment with analogues of the SERCA-inhibitor Thapsigargin is a promising new approach for a wide variety of cancer entities. However, our previous studies on various tumor cells suggested resistance of\n                    <jats:italic>SEC62<\/jats:italic>\n                    over-expressing tumors to this treatment. Therefore, we proposed the novel concept that e.g. lung-, prostate-, and thyroid-cancer patients should be tested for\n                    <jats:italic>SEC62<\/jats:italic>\n                    over-expression, and developed a novel therapeutic strategy for a combinatorial treatment of\n                    <jats:italic>SEC62<\/jats:italic>\n                    over-expressing tumors. The latter was based on the observations that treatment of\n                    <jats:italic>SEC62<\/jats:italic>\n                    over-expressing tumor cells with\n                    <jats:italic>SEC62<\/jats:italic>\n                    -targeting siRNAs showed less resistance to Thapsigargin as well as a reduction in migratory potential and that the siRNA effects can be mimicked by the Calmodulin antagonist Trifluoperazine. Therefore, the combinatorial treatment of\n                    <jats:italic>SEC62<\/jats:italic>\n                    over-expressing tumors was proposed to involve Thapsigargin and Trifluoperazine. Here, we addressed the impact of Thapsigargin and Trifluoperazine in separate and combined treatments of heterotopic tumors, induced by inoculation of human hypopharyngeal squamous cell carcinoma (FaDu)-cells into the mouse flank. Seeding of the tumor cells and\/or their growth rate were significantly reduced by all three treatments, suggesting Trifluoperazine is a small molecule to be considered for future therapeutic strategies for patients, suffering from Sec62-overproducing tumors.\n                  <\/jats:p>","DOI":"10.1515\/bmc-2018-0006","type":"journal-article","created":{"date-parts":[[2018,5,20]],"date-time":"2018-05-20T18:15:41Z","timestamp":1526840141000},"page":"53-63","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of\n                    <i>SEC62<\/i>\n                    over-expressing tumors by Thapsigargin and Trifluoperazine"],"prefix":"10.1515","volume":"9","author":[{"given":"Christina","family":"K\u00f6rbel","sequence":"first","affiliation":[{"name":"Institute for Clinical and Experimental Surgery , Saarland University , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Linxweiler","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology , Head and Neck Surgery , Saarland University Hospital , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bochen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology , Head and Neck Surgery , Saarland University Hospital , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Wemmert","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology , Head and Neck Surgery , Saarland University Hospital , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schick","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology , Head and Neck Surgery , Saarland University Hospital , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology , Saarland University , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Toxicology , Saarland University , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Menger","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Experimental Surgery , Saarland University , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology , Saarland University , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Greiner","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology , Saarland University , Homburg\/Saar , saabrucken , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,5,19]]},"reference":[{"key":"2026053116135425677_j_bmc-2018-0006_ref_001_w2aab3b7c99b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Hirsch F.R., Suda K., Wiens J., and Bunn P.A. Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet, 2016, 388, 1012-1024.","DOI":"10.1016\/S0140-6736(16)31473-8"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_002_w2aab3b7c99b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Andersen T.B., Lopez C.Q., Manczak T., Martinez, K., and Simonsen, H.T. Thapsigargin--from Thapsia L. to mipsagargin. Molecules, 2015, 20, 6113-6127.","DOI":"10.3390\/molecules20046113"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_003_w2aab3b7c99b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Mahalingam D., Wilding G., Denmeade S., Sarantopoulas J., Cosgrove D., Cetnar J., et al. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. Br. J. Cancer 2016, 114, 986-994.","DOI":"10.1038\/bjc.2016.72"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_004_w2aab3b7c99b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Xu C., Ma H., Inesi G., Al-Shawi M.K., and Toyoshima C. Specific structural requirements for the inhibitory effect of thapsigargin on the Ca2+ ATPase SERCA. J Biol Chem, 2004, 279, 17973-17979.","DOI":"10.1074\/jbc.M313263200"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_005_w2aab3b7c99b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Jakobsen C.M., Denmeade S.R., Isaacs J.T., Gady A., Olsen C.E., and Christensen S.B. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. Journal of Medicinal Chemistry, 2001, 44, 4696-4703.","DOI":"10.1021\/jm010985a"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_006_w2aab3b7c99b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Andrews S.P., Tait M.M., Ball, M., and Ley, S.V. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin. Org & Biomol Chem, 2007, 5, 1427-1436.","DOI":"10.1039\/b702481a"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_007_w2aab3b7c99b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Dubois C., Vanden Abeele, F., Sehgal, P., Olesen, C., Junker, S., Christensen, S.B., et al. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium. FEBS J, 2013, 280, 5430-5440.","DOI":"10.1111\/febs.12475"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_008_w2aab3b7c99b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Vander Griend D.J., Antony L., Dalrymple S.L., Xu Y., Christensen S.B., Denmeade S.R., and Isaacs J.T. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther, 2009, 8, 1340-1349.","DOI":"10.1158\/1535-7163.MCT-08-1136"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_009_w2aab3b7c99b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Denmeade S.R. and Isaacs, J.T. The SERCA pump as a therapeutic target: making a \u201csmart bomb\u201d for prostate cancer. Cancer Biol Ther, 2005, 4, 14-22.","DOI":"10.4161\/cbt.4.1.1505"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_010_w2aab3b7c99b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Denmeade S.R., Jakobsen C.M., Janssen S., Khan S.R., Garrett E.S., Lilja H., et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst, 2003, 95, 990-1000.","DOI":"10.1093\/jnci\/95.13.990"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_011_w2aab3b7c99b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Doan N.T., Paulsen E.S., Sehgal P., Moller J.V., Nissen P., Denmeade S.R., et al. Targeting thapsigargin towards tumors. Steroids, 2015, 97, 2-7.","DOI":"10.1016\/j.steroids.2014.07.009"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_012_w2aab3b7c99b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Wang H.L., Wang S.S., Song W.H., Pan Y., Yu H.P., Si T.G., et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One, 2015, 10, e0125924.","DOI":"10.1371\/journal.pone.0125924"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_013_w2aab3b7c99b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Greiner M., Kreutzer B., Lang S., Jung V., Adolpho C., Unteregger G., et al. Sec62 protein content is crucial for the ER stress tolerance of prostate cancer. The Prostate, 2011, 71, 1074-1083.","DOI":"10.1002\/pros.21324"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_014_w2aab3b7c99b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Meyer H.A., Grau H., Kraft R., Kostka S., Prehn S., Kalies K.U., and Hartmann E. Mammalian Sec61 is associated with Sec62 and Sec63. J Biol Chem, 2000, 275, 14550-14557.","DOI":"10.1074\/jbc.275.19.14550"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_015_w2aab3b7c99b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Tyedmers J., Lerner M., Bies C., Dudek J., Skowronek M.H., Haas I.G., et al. Homologs of the yeast Sec complex subunits Sec62p and Sec63p are abundant proteins in dog pancreas microsomes. Proc Natl Acad Sci USA, 2000, 97, 7214-7219.","DOI":"10.1073\/pnas.97.13.7214"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_016_w2aab3b7c99b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Muller L., de Escauriaza M.D., Lajoie P., Theis M., Jung M., Muller A., et al. Evolutionary gain of function for the ER membrane protein Sec62 from yeast to humans. Mol Biol Cell, 2010, 21, 691-703.","DOI":"10.1091\/mbc.e09-08-0730"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_017_w2aab3b7c99b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Lang S., Erdmann F., Jung M., Wagner R., Cavalie A., and Zimmermann, R. Sec61 complexes form ubiquitous ER Ca2+ leak channels. Channels (Austin), 2011, 5, 228-235.","DOI":"10.4161\/chan.5.3.15314"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_018_w2aab3b7c99b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Erdmann F., Schauble N., Lang S., Jung M., Honigmann A., Ahmad M., et al. Interaction of calmodulin with Sec61alpha limits Ca2+ leakage from the endoplasmic reticulum. EMBO J, 2011, 30, 17-31.","DOI":"10.1038\/emboj.2010.284"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_019_w2aab3b7c99b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Harsman A., Kopp A., Wagner R., Zimmermann R., and Jung M. Calmodulin regulation of the calcium-leak channel Sec61 is unique to vertebrates. Channels (Austin) 2011, 5, 293-298.","DOI":"10.4161\/chan.5.4.16160"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_020_w2aab3b7c99b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Schauble N., Lang S., Jung M., Cappel S., Schorr S., Ulucan O., et al. BiP-mediated closing of the Sec61 channel limits Ca2+ leakage from the ER. EMBO J, 2012, 31, 3282-3296.","DOI":"10.1038\/emboj.2012.189"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_021_w2aab3b7c99b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Linxweiler M., Schorr S., Schauble N., Jung M., Linxweiler J., Langer F., et al. Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer, 2013, 13, 574.","DOI":"10.1186\/1471-2407-13-574"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_022_w2aab3b7c99b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Greiner M., Kreutzer B., Jung V., Grobholz R., Hasenfus A., Stohr R.F., et al. Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer, 2011a, 128, 2284-2295.","DOI":"10.1002\/ijc.25580"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_023_w2aab3b7c99b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Linxweiler M., Linxweiler J., Barth M., Benedix J., Jung V., Kim Y.J., et al. Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol, 2012, 180, 473-483.","DOI":"10.1016\/j.ajpath.2011.10.039"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_024_w2aab3b7c99b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Wemmert S., Willnecker V., Kulas P., Weber S., Lerner C., Berndt S., et al. Identification of CTNNB1 mutations, CTNNB1 amplifications, and an Axin2 splice variant in juvenile angiofibromas. Tumour Biol, 2016, 37, 5539-5549.","DOI":"10.1007\/s13277-015-4422-y"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_025_w2aab3b7c99b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Tomayko M.M. and Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol, 1989, 24,148-154.","DOI":"10.1007\/BF00300234"},{"key":"2026053116135425677_j_bmc-2018-0006_ref_026_w2aab3b7c99b1b6b1ab2b1c26Aa","unstructured":"Remmele W. and Stegner H.E. Recommendation for uniform definition of an immunreactive score (IRS) for immunohistochemical detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8, 138-140."},{"key":"2026053116135425677_j_bmc-2018-0006_ref_027_w2aab3b7c99b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Tang L., Shukla P.K., and Wang Z.J. Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance. Neurosci Lett, 2006, 397, 1-4.","DOI":"10.1016\/j.neulet.2005.11.050"}],"container-title":["Biomolecular Concepts"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/bmc\/9\/1\/article-p53.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2018-0006\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2018-0006\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T16:14:00Z","timestamp":1780244040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/bmc-2018-0006\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,5,19]]},"published-print":{"date-parts":[[2018,5,19]]}},"alternative-id":["10.1515\/bmc-2018-0006"],"URL":"https:\/\/doi.org\/10.1515\/bmc-2018-0006","relation":{},"ISSN":["1868-503X","1868-5021"],"issn-type":[{"value":"1868-503X","type":"electronic"},{"value":"1868-5021","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1,1]]}}}